Arrowhead Pharmaceuticals Shares Down 14.2%; FBR B. Riley's Madhu Kumar Tells Benzinga Investors Are Perceiving HBV Collab. With Janssen As Arrowhead 'Giving Away' Its Lead Asset, Making Co. Less Of An Acquisition Target